REG - Sareum Holdings PLC - Annual General Meeting Statement

Sareum HoldingsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI7005Ka&default-theme=true

RNS Number : 7005K  Sareum Holdings PLC  09 December 2025

Sareum Holdings PLC

("Sareum" or the "Company")

Annual General Meeting Statement

Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer publishes an update on operations
and pipeline progress ahead of its Annual General Meeting ("AGM") taking place
today at the offices of ICR Healthcare, 85 Gresham Street, London EC2V 7NQ.

During the AGM, the Company's Executive Chairman, Dr Stephen Parker, will
provide the following update on Sareum's progress across its pipeline
programmes.

The Company has continued to advance its lead programme, SDC-1801, following
the successful completion of its Phase 1 clinical trial in 2024. Despite a
temporary setback with the discontinuation of a toxicology study, the Company
has made significant operational progress, including the appointment of a
leading global contract research organisation (CRO), and is now
well-positioned to restart these important studies and advance towards Phase 2
development.

SDC-1801 (autoimmune disease)

SDC-1801, Sareum's selective TYK2/JAK1 inhibitor, remains positioned as a
potential treatment for a range of autoimmune diseases, with an initial focus
on psoriasis, an autoimmune condition affecting the skin.

As previously announced, SDC-1801 has completed Phase 1 clinical development.
A randomised, placebo-controlled trial demonstrated that SDC-1801 achieved
blood plasma levels significantly exceeding the predicted therapeutic
exposure, with a half-life of 17-20 hours supporting once-daily dosing with a
smooth delivery of drug over the dosing period. Importantly, no deaths or
serious adverse events due to SDC-1801 were reported, and the frequency of
adverse events (all mild or moderate) was similar in the active and placebo
groups.

Notably, SDC-1801 has not exhibited any of the potentially dose-limiting side
effects that have been observed with leading dual TYK2/JAK1 inhibitors in
clinical development, reinforcing the molecule's differentiated profile and
best-in-class potential.

Following successful completion of the clinical trial, two large-scale batches
of SDC-1801 have been manufactured: one under GMP conditions for future
planned clinical studies, and a non-GMP batch for the Phase 2 enabling
toxicology studies. Process chemistry improvements have enhanced the purity
profile of SDC-1801 while maintaining good manufacturing yield.

A programme of work to optimise the capsule formulation of SDC-1801 is
underway, aimed at enhancing drug release at higher doses and reducing the
number of capsules required per dose in future clinical trials. Considerable
progress has been made, and the Company expects this project to conclude in Q1
2026.

As announced on 10 October 2025, the Company discontinued its 16-week GLP
preclinical toxicology study for SDC-1801 following unexpected safety
findings, observed by the third-party provider of the study. These findings
occurred at a higher incidence in control-group animals that received an
inactive dosing solution compared to those dosed with SDC-1801.

The Company has now appointed a different leading global CRO, with extensive
experience in long-term toxicology studies, to restart the Phase 2-enabling
toxicology programme. Prior to commencing the full 16-week toxicology study,
the Company will conduct a separate pharmacokinetic (PK) study to evaluate
four different formulations, three liquid formulations for gavage dosing and
one capsule formulation. This five-day study will provide valuable data on
both tolerability and exposure levels, helping to optimise the formulation
selection for the full toxicology study. The carrier formulation is specific
to the animal toxicology studies only and will not form part of any human
dosing regimen.

The PK study is expected to commence imminently, with the full toxicology
study expected to restart as early as possible in Q1 2026. Both studies will
be completed using the Company's existing cash resources and the existing
toxicology batch of SDC-1801.

SDC-1802 (cancer immunotherapy)

Translational studies with SDC-1802 have been completed, providing a solid
data package to support potential further development. The strongest cancer
response was seen in haematological cancers, with significant unmet medical
need, including T-ALL and B-cell lymphoma.

The Company is reviewing how best to progress SDC-1802 into clinical
development and notes that partnering may be the preferred route at this
stage.

SRA737 (cancer)

SRA737 is a clinical-stage oral, selective inhibitor of checkpoint kinase 1
(Chk1) that targets cancer cell replication and DNA damage repair mechanisms.

In March 2025, the former US licence arrangement for SRA737 was terminated and
the asset reverted to the CRT Pioneer Fund (CPF). Sareum successfully acquired
the licence for SRA737 following this termination, renegotiating significantly
improved economic terms. The Company now receives 63.5% of all future revenues
compared to 27.5% under the former agreement, at no cost to the Company.

The Company continues to explore partnering opportunities for SRA737, building
on positive Phase 1/2 data that demonstrated good tolerability as monotherapy
and promising activity in combination with low-dose gemcitabine in anogenital
cancers, an area of significant unmet medical need.

Furthermore, Sareum has maintained an Investigational New Drug (IND)
application with the United States Food and Drug Administration (FDA), opened
by the previous licence holder, to conduct a Phase 1 trial in patients with
acute myeloid leukaemia and myelodysplastic syndromes. The Company retains
sufficient stock of SRA737 capsules to conduct such a trial.

The Company remains confident in the potential of SRA737 and is assessing the
most effective routes to progress and create value from this asset.

TYK2 Neuroscience Programme (CNS)

Sareum has initiated a collaboration with Receptor.AI to accelerate discovery
of blood-brain barrier (BBB)-penetrant, isoform-selective TYK2/JAK1 inhibitors
for potential use in neuro-inflammatory indications such as multiple sclerosis
and Parkinson's disease.

This programme builds on earlier preclinical work from the Company's SKIL
platform, which demonstrated blood-brain barrier permeability of selected
TYK2/JAK1 molecules. The collaboration extends the relevance of Sareum's
TYK2/JAK1 expertise into central nervous system diseases, areas of increasing
scientific and commercial interest.

A first batch of compounds have been designed and synthesized and are
currently undergoing testing in biochemical assays to assess their potency
against the JAK kinases, and in early-stage absorption, distribution,
metabolism and excretion (ADME) assays to assess their potential to cross the
blood-brain barrier and give sufficient exposure at the target site.

 

Future Direction

As part of a broader value-realisation strategy, Sareum has engaged a
specialist US-based business development consultancy to actively broaden and
accelerate ongoing partnering discussions for SDC-1801 and SRA737.

The Board continues to prioritise non-dilutive funding routes to advance the
pipeline and protect shareholder value, with current core activities funded
from existing cash resources.

Sareum continues to review the optimum level of staffing for the Company,
including Chief Medical Officer and Chief Executive Officer roles.

Summary

Sareum has made substantial progress across its pipeline during 2025. The
positive Phase 1 data for SDC-1801, together with the competitive profile
versus other TYK2/JAK1 inhibitors in development, continues to support
SDC-1801's potential as a best-in-class, once-daily oral therapy for
autoimmune diseases. Despite the frustrating delay to the toxicology study,
the Company's confidence in the molecule remains strong, and the study is now
on track to restart in Q1 2026.

The significantly improved economic terms for SRA737, coupled with active
partnering discussions for this asset and SDC-1802, position the Company to
create value across its portfolio. The new TYK2 neuroscience collaboration
adds further long-term potential. The Company has engaged specialist business
development consultants to support partnering efforts across key programmes.

With strengthened intellectual property, a clear operational roadmap, active
business development initiatives, and sufficient financial resources, the
Company enters the new period with confidence and a clear set of
value-creating milestones ahead.

We would like to thank our shareholders and other stakeholders for their
continued support.

AGM Webcast

A live webcast to the investment community will be made available online via
the Investor Meet Company platform. Existing and potential investors wishing
to participate in the presentation can register on
www.investormeetcompany.com/sareum-holdings-plc/register-investor
(http://www.investormeetcompany.com/sareum-holdings-plc/register-investor) .
Questions can be submitted before the event via the Investor Meet Company
dashboard or at any time via the live presentation via the "Ask a Question"
function. Responses from the Q&A session will be published at the earliest
opportunity on the IMC platform.

Shareholders are reminded that attendance online will not constitute
attendance at the AGM and shareholders will not be able to vote on the day.

- ENDS-

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman                  01223 497700

                                                     ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Singer Capital Markets (Joint Corporate Broker)     020 7496 3000

 Phil Davies

 Oberon Capital (Joint Corporate Broker)             020 3179 5300

 Mike Seabrook / Nick Lovering

 ICR Healthcare (Financial PR)                       020 3709 5700

 Jessica Hodgson / Davide Salvi

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for certain haematological cancers and has recently initiated a
preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory
diseases such as multiple sclerosis and Parkinson's disease

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(https://sareum.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMUWVSRVNUURAA



            Copyright 2019 Regulatory News Service, all rights reserved